CareDx (CDNA) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
CareDx Reports Fourth Quarter and Full Year 2019 Results
February 27, 2020 4:05 PM ESTSOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2019.
Recent Highlights:
Achieved total revenue of $35.8 million for the three months ended December 31, 2019, increasing 52% year-over-yearProvided over 14,000 patient results in the fourth quarter and approximately 49,000 patient results in 2019As of December 31, 2019, over 30 U.S.-based transplant centers... More


